SUPN FY 2013 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

FY 2013 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$12M+712.1% YoY

Gross Profit

$11M90.8% margin

Operating Income

-$62M-515.2% margin

Net Income

-$92M-767.7% margin

EPS (Diluted)

$-2.90

Cash Flow

Operating Cash Flow

-$58M

Free Cash Flow

-$60M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$111M

Total Liabilities

$78M

Stockholders' Equity

$33M

Cash & Equivalents

$82M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$1M	+712.1%
Gross Profit	$11M	$1M	+637.5%
Operating Income	-$62M	-$42M	-46.8%
Net Income	-$92M	-$46M	-99.4%